Literature DB >> 10805211

Essential pathogenetic role for interferon (IFN-)gamma in concanavalin A-induced T cell-dependent hepatitis: exacerbation by exogenous IFN-gamma and prevention by IFN-gamma receptor-immunoglobulin fusion protein.

F Nicoletti1, P Zaccone, M Xiang, G Magro, M Di Mauro, R Di Marco, G Garotta, P Meroni.   

Abstract

We have studied the effects of either exogenously-administered interferon (IFN-)gamma or of a nonimmunogenic mouse IFN-gamma receptor-Immunoglobulin (IFN-gamma R-Ig) fusion protein on the development of Concanavalin (Con)A-induced hepatitis in NMRI mice. PBS-treated control mice injected with 20 mg/kg ConA developed classical serological and histological signs of hepatitis with elevation of transaminases in the blood and infiltration of the liver by mononuclear cells and neutrophils. Treating the mice with rat IFN-gamma 24 h prior to and 1 h after ConA-challenge markedly exacerbated these signs of hepatitis in a dose-dependent fashion. Moreover, mice injected with lower, non hepatitogenic, doses of ConA (10, 5 mg/kg) became fully susceptible to develop hepatitis upon similar treatment with IFN-gamma. Concordantly, ConA-induced hepatitis was abrogated by either IFN-gamma R-Ig fusion protein or anti-IFN-gamma mAb. These data provide further evidence for the central pathogenetic role of endogenous IFN-gamma in ConA-induced hepatitis and demonstrate the feasibility to prevent disease development by means of a non immunogenic IFN-gamma R-Ig fusion protein.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10805211     DOI: 10.1006/cyto.1999.0561

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  9 in total

Review 1.  New insights into Nod-like receptors (NLRs) in liver diseases.

Authors:  Tao Xu; Yan Du; Xiu-Bin Fang; Hao Chen; Dan-Dan Zhou; Yang Wang; Lei Zhang
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2018-03-10

2.  The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury.

Authors:  Christian Klein; Torsten Wüstefeld; Ulrike Assmus; Tania Roskams; Stefan Rose-John; Michael Müller; Michael P Manns; Mattias Ernst; Christian Trautwein
Journal:  J Clin Invest       Date:  2005-03-03       Impact factor: 14.808

Review 3.  Regulation of hepatocyte fate by interferon-γ.

Authors:  Christopher J Horras; Cheri L Lamb; Kristen A Mitchell
Journal:  Cytokine Growth Factor Rev       Date:  2011-02-18       Impact factor: 7.638

4.  PK/PD Modeling of the PDE7 Inhibitor-GRMS-55 in a Mouse Model of Autoimmune Hepatitis.

Authors:  Artur Świerczek; Hanna Plutecka; Marietta Ślusarczyk; Grażyna Chłoń-Rzepa; Elżbieta Wyska
Journal:  Pharmaceutics       Date:  2021-04-21       Impact factor: 6.321

5.  Ameliorated ConA-induced hepatitis in the absence of PKC-theta.

Authors:  Xianfeng Fang; Ruiqing Wang; Jian Ma; Yan Ding; Weirong Shang; Zuoming Sun
Journal:  PLoS One       Date:  2012-02-07       Impact factor: 3.240

Review 6.  Immune mediated liver failure.

Authors:  Xiaojing Wang; Qin Ning
Journal:  EXCLI J       Date:  2014-10-01       Impact factor: 4.068

7.  Lower level of IL‑35 and its reduced inhibition in Th17 cells in patients with bone marrow mononuclear cells Coombs test‑positive hemocytopenia.

Authors:  Yi Li; Yihao Wang; Hui Liu; Kai Ding; Shanfeng Hao; Yuanyuan Shao; Honglei Wang; Jin Chen; Lei Huang; Zonghong Shao; Rong Fu
Journal:  Mol Med Rep       Date:  2017-12-11       Impact factor: 2.952

8.  Kupffer cells promote T-cell hepatitis by producing CXCL10 and limiting liver sinusoidal endothelial cell permeability.

Authors:  Shen Dai; Fengming Liu; Zhongnan Qin; Jinyan Zhang; Jiayi Chen; Wen-Xing Ding; Dechun Feng; Yong Ji; Xuebin Qin
Journal:  Theranostics       Date:  2020-06-01       Impact factor: 11.556

Review 9.  The Role of Gut-Derived Microbial Antigens on Liver Fibrosis Initiation and Progression.

Authors:  Dishen Chen; Thanh H Le; Haleh Shahidipour; Scott A Read; Golo Ahlenstiel
Journal:  Cells       Date:  2019-10-27       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.